PUBLIC COMPANY
save$RLAYRelay Therapeutics, Inc.
$RLAY19.86-0.35%Cambridge, MA, USupdated 11h ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- phase2A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
- phase1First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- phase1First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (2)
- Apr 9, 26option exerciseCatinazzo Thomas · Chief Financial Officer1,800 sh
- Apr 9, 26option exerciseCatinazzo Thomas · Chief Financial Officer1,800 sh
🐶 Hiring Signal
next earnings Nov 5, 2026
Where Relay Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaOncology 1Rare Disease 1
News
- Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast CancerCapivasertib plus fulvestrant generated a numerical OS benefit vs placebo plus fulvestrant in PIK3CA/AKT1/PTEN-altered advanced breast cancer.onclive · 3mo ago
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that